Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for terazosin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on terazosin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on terazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. A multicenter, double-blind study compared the antihypertensive efficacy and safety of doxazosin and terazosin as once-daily therapy. Doxazosin, a potent antihypertensive agent, selectively inhibits alpha 1 adrenoceptors. Its pharmacokinetic profile, including gradual onset of action, long plasma elimination half-life and long duration of action, permits once-daily dosing. Terazosin, a structural (...) analog of prazosin, also inhibits alpha 1 adrenoceptors and is recommended as once or twice-daily therapy. Nineteen (73%) of 26 patients randomly assigned to receive doxazosin were therapeutic successes; 17 (65%) achieved normalized blood pressure (defined as blood pressure less than or equal to 90 mm Hg). The mean final daily dosage in patients classified as therapeutic successes was 2.4 mg. Eighteen (64%) of 28 terazosin-treated patients were considered therapeutic successes; 16 (57%) achieved
Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
WITHDRAWN: Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched (...) in computerized general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers.Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls.Study, patient characteristics and outcomes data were extracted in duplicate onto standardized forms utilizing a prospectively developed protocol. The main outcome measure
Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) ) treatment with finasteride, terazosin, and transurethral resection of the prostate for men (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical population of men aged 55-75 years with at least moderate symptoms of prostatism. Setting The practice setting was hospital. The economic study was carried out in the US. Dates to which data relate Effectiveness data were obtained between 1988-1994. Resource data were obtained between 1994-1995
[An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis]. An open randomized comparative trial of setegis (terazosine) has shown good subjective and objective results in patients with chronic bacterial prostatitis. The drug is well tolerated and produces insignificant side effects. It is also demonstrated that combined therapy with alpha-adrenoblockers is more effective
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.We compared the safety and efficacy (...) of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons
Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review. PubMed, Embase, the Cochrane Library, Chinese biomedicine literature database (CBM), reference lists of reports, and reviews were searched for randomized controlled trials (RCTs), or quasi-RCTs of tamsulosin versus terazosin in BPH. Twelve studies involving 2,816 men (...) were included. Outcomes included international prostate symptom score (IPSS), quality of life (QOL), maximum urinary flow rate (Q(max)), average urinary flow rate (Q(ave)), residual volume, prostate volume, and adverse effect (dizziness, severe hypotension, dry mouth). Relative risk was calculated for dichotomous data. Sensitivity analyses assessed the influence of baseline symptom severity. We found that tamsulosin is better than terazosin when assessed by IPSS (weighted mean difference (WMD
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension.We randomly divided 360 LUTS patients with concomitant hypertension into a 5 mg amlodipine group, a 2 mg terazosin (...) group and a 5 mg amlodipine plus 2 mg terazosin group, and measured PVR at the baseline and 4 weeks after the treatment.For male patients with LUTS associate with hypertension, all of amlodipine (APVR = 6.8) , terazosin (APVR = 7. 6), and combination group (APVR = 8.8) can significant reduced the PVR (P < . 0.1), but no significant difference was found among three groups.Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin (ADIES) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00449683 Recruitment Status : Completed First Posted : March 20, 2007 Last Update Posted : August 25, 2016 Sponsor: Thomas Jefferson
Terazosin Top results for terazosin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for terazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38 (...) ), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5).After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group
Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting (TZ-CAS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03195673 Recruitment Status
Terazosin activated Pgk1 and Hsp90 to promote stress resistance Drugs that can protect against organ damage are urgently needed, especially for diseases such as sepsis and brain stroke. We discovered that terazosin (TZ), a widely marketed α1-adrenergic receptor antagonist, alleviated organ damage and improved survival in rodent models of stroke and sepsis. Through combined studies of enzymology and X-ray crystallography, we discovered that TZ binds a new target, phosphoglycerate kinase 1 (Pgk1
Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. Chronic administration of alpha 1-receptor antagonists is associated with loss of clinical efficacy, especially in congestive heart failure, although the mechanism is uncertain. To evaluate changes in venous alpha 1-adrenoceptor responsiveness during chronic alpha 1-adrenoceptor blockade, dose-response curves to phenylephrine and angiotensin II were constructed in 10 healthy subjects before (...) , during, and after administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). However, by day 28, the dose-response curve had shifted back towards baseline with an ED50 of 112 ng/min. After discontinuing terazosin, the ED50 for phenylephrine remained near the baseline value, indicating no evidence
Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 8583558 1996 03 19 2017 09 08 0022-5347 155 3 1996 Mar The Journal of urology J. Urol. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. 1039 Frankel G G eng Comment Letter United States J Urol 0376374 0022-5347 0 Adrenergic alpha-Antagonists 8L5014XET7 Terazosin XM03YJ541D Prazosin AIM IM J Urol
The influence of food on the oral bioavailability of terazosin. 1685091 1992 02 27 2018 11 13 0306-5251 32 6 1991 Dec British journal of clinical pharmacology Br J Clin Pharmacol The influence of food on the oral bioavailability of terazosin. 775-6 McNeil J J JJ Drummer O H OH Raymond K K Conway E L EL Louis W J WJ eng Clinical Trial Letter Randomized Controlled Trial Research Support, Non-U.S. Gov't England Br J Clin Pharmacol 7503323 0306-5251 0 Adrenergic alpha-Antagonists 8L5014XET7 (...) Terazosin XM03YJ541D Prazosin IM Administration, Oral Adrenergic alpha-Antagonists pharmacokinetics Adult Biological Availability Food Humans Middle Aged Prazosin analogs & derivatives pharmacokinetics 1991 12 1 1991 12 1 0 1 1991 12 1 0 0 ppublish 1685091 PMC1368564 Br J Clin Pract Suppl. 1987 Dec;54:9-14 2905162 Am J Med. 1986 May 23;80(5B):20-4 2872802 Clin Pharmacokinet. 1980 Nov-Dec;5(6):583-90 7438656 Prostate Suppl. 1990;3:75-84 1689172 Am J Cardiol. 1990 Mar 1;65(9):638-43 1968703 J Cardiovasc
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Pharmacotherapy for the treatment of BPH is currently being targeted to relax prostate smooth muscle (alpha blockade) and decrease prostate volume (androgen suppression). The objective of the present study was to determine the relative efficacy of terazosin vs. terazosin and flutamide (combination therapy) for the treatment of symptomatic BPH. Twenty-nine males with symptomatic BPH were (...) enrolled into this 6-month open label study. The entry criteria included peak urinary flow rate between 4-15 ml/sec, a total Boyarsky symptom score greater than 7, and postvoid residual less than 300 ml. The daily dosage of terazosin was titrated to 5 mg over a 2-week interval. A 750 mg daily dosage of flutamide was added following 1 month of terazosin monotherapy. The dosages were lowered if significant adverse events developed. Efficacy assessments were performed at 1 month (terazosin alone), 6
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. Terazosin is a new, long-acting, selective, postsynaptic alpha 1-adrenergic receptor antagonist with a chemical structure similar to that of prazosin. In this article the pharmacokinetics of terazosin are reviewed, and the incidence of adverse events in a dose-response study and a meta-analysis of 20 placebo-controlled trials involving a total of 1814 patients is presented. Peak plasma concentrations (...) of terazosin are achieved 1 to 2 hours after oral administration. The relatively long half-life of terazosin (12 hours) enables it to be administered in a once-a-day regimen. Dose and plasma levels of terazosin show a linear relationship. Terazosin is rapidly and completely absorbed after oral administration. The pharmacokinetics of terazosin are not significantly affected by food, age, hypertension, or renal impairment. Adverse events after the administration of terazosin are usually minor and not age
Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension. The effects of selective alpha 1-adrenergic blockade with the agent terazosin on blood pressure and cardiovascular pressor responsiveness as related to major pressor factors were assessed in 17 patients with mild to moderate essential hypertension (mean age +/- s.e.m. 48 +/- 2 years). As compared with a 2-week placebo period, terazosin, given during 8 weeks (...) rate, body weight, exchangeable sodium, blood volume, NE plasma clearance, plasma epinephrine, renin, angiotensin (ANG) II and aldosterone levels, the relationships between the ANG II-induced increases in arterial pressure or plasma aldosterone and the concomitant increments of plasma ANG II during ANG II infusion as well as the heart rate responsiveness to isoproterenol did not change significantly after terazosin. The findings of the present study suggest that the fall of arterial pressure